



Council of the European Union
General Secretariat

Brussels, 18 December 2020

CM 5447/20

JAI
CORDROGUE
SAN
COSI
RELEX
UD
PROCED

COMMUNICATION

WRITTEN PROCEDURE

Contact: hdg@consilium.europa.eu
Tel./Fax: +32.2-281.94.58

Subject: END OF WRITTEN PROCEDURE
EU Drugs Strategy 2021-2025
- Approval

Delegations are informed that the written procedure, opened by CM 5424/20 of 17 December 2020 was completed on 18 December 2020 at 17:00 and that all delegations agreed to the approval of the "EU Drugs Strategy 2021-2025", as set out in document 13932/20.

Therefore, the above Conclusions of the Council entitled "EU Drugs Strategy 2021 - 2025" are approved.

The statement by Poland is reproduced in the Annex to this CM.

Statement by Poland

“Statement of the Republic of Poland on Drugs Strategy of the European Union 2021 – 2025. In relation to the Drugs Strategy of the European Union 2021 - 2025, Poland understands wording “gender equality” (point 2 of the Introduction and point. 9.6 of the Strategy) as referring to “equality between women and men”, in line with art. 2 and art. 3 of the Treaty on European Union. Also Poland understands wording “gender” (point 4 of the Introduction and point 6.3) as referring to “sex” in line with art. 10, art. 19 para 1 and art. 157 para 2 and 4 of the Treaty on the Functioning of the European Union, and on the same basis Poland understands phrase “the gender perspective” (point 6.3) as referring to “the perspective of sex” .
